Alnylam-话题@MedSci

#Alnylam#

15篇内容 | 1322人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2093040, encodeId=78e320930403e, content=<a href='/topic/show?id=0b2115543c9' target=_blank style='color:#2F92EE;'>#RNAi药物#</a><a href='/topic/show?id=be56234245' target=_blank style='color:#2F92EE;'>#Alnylam#</a> <a href='/topic/show?id=e33910494e3c' target=_blank style='color:#2F92EE;'>#lumasiran#</a>治疗<a href='/topic/show?id=a9df1049489d' target=_blank style='color:#2F92EE;'>#原发性高草酸尿症1型#</a>, objectTitle=FDA批准lumasiran治疗原发性高草酸尿症1型，Alnylam的RNAi帝国再下一城！, objectType=article, longId=742814, objectId=e662e42814a9, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20221009/b9af039519294fe2903286c1e746ebea.jpg, objectUrl=/article/show_article.do?id=e662e42814a9, replyNumber=0, likeNumber=141, createdTime=2022-10-11, rootId=0, userName=lifestar, userId=aa0e14, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e662e42814a9, moduleTitle=FDA批准lumasiran治疗原发性高草酸尿症1型，Alnylam的RNAi帝国再下一城！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e662e42814a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1704838, encodeId=78a21e0483827, content=<a href='/topic/show?id=be56234245' target=_blank style='color:#2F92EE;'>#Alnylam#</a>, objectTitle=RNAi治疗COVID-19：Alnylam与Vir Biotechnology联手开发, objectType=article, longId=189413, objectId=9aac1894137a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9aac1894137a, replyNumber=0, likeNumber=66, createdTime=2020-08-05, rootId=0, userName=zz12341244, userId=cfb930846673, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9aac1894137a, moduleTitle=RNAi治疗COVID-19：Alnylam与Vir Biotechnology联手开发, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9aac1894137a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1704844, encodeId=b1361e048448c, content=<a href='/topic/show?id=be56234245' target=_blank style='color:#2F92EE;'>#Alnylam#</a>, objectTitle=RNAi巨头Alnylam公司再发力：出击非酒精性脂肪性肝炎（NASH）, objectType=article, longId=198731, objectId=37c9198e311c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=37c9198e311c, replyNumber=0, likeNumber=75, createdTime=2020-11-24, rootId=0, userName=zz12341244, userId=cfb930846673, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=37c9198e311c, moduleTitle=RNAi巨头Alnylam公司再发力：出击非酒精性脂肪性肝炎（NASH）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=37c9198e311c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1704843, encodeId=60e61e0484363, content=<a href='/topic/show?id=be56234245' target=_blank style='color:#2F92EE;'>#Alnylam#</a>, objectTitle=ERA-EDTA 2020：RNAi疗法公司Alnylam再发力！Lumasiran治疗1型原发性高草酸尿症III期临床成功, objectType=article, longId=195493, objectId=6fc619549390, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6fc619549390, replyNumber=0, likeNumber=84, createdTime=2021-04-30, rootId=0, userName=zz12341244, userId=cfb930846673, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6fc619549390, moduleTitle=ERA-EDTA 2020：RNAi疗法公司Alnylam再发力！Lumasiran治疗1型原发性高草酸尿症III期临床成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6fc619549390)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1704842, encodeId=63f71e048424c, content=<a href='/topic/show?id=be56234245' target=_blank style='color:#2F92EE;'>#Alnylam#</a>, objectTitle=FDA为Alnylam的RNAi疗法Lumasiran授予优先审查，用于治疗1型原发性高草酸尿症, objectType=article, longId=194823, objectId=beb619482390, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=beb619482390, replyNumber=0, likeNumber=93, createdTime=2020-10-04, rootId=0, userName=zz12341244, userId=cfb930846673, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=beb619482390, moduleTitle=FDA为Alnylam的RNAi疗法Lumasiran授予优先审查，用于治疗1型原发性高草酸尿症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=beb619482390)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1704839, encodeId=280e1e0483968, content=<a href='/topic/show?id=be56234245' target=_blank style='color:#2F92EE;'>#Alnylam#</a>, objectTitle=Alnylam的第二款RNAi药物Givlaari，获得欧盟批准治疗肝卟啉症, objectType=article, longId=189441, objectId=02d9189441ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=02d9189441ee, replyNumber=0, likeNumber=71, createdTime=2020-09-14, rootId=0, userName=zz12341244, userId=cfb930846673, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=02d9189441ee, moduleTitle=Alnylam的第二款RNAi药物Givlaari，获得欧盟批准治疗肝卟啉症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=02d9189441ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1704836, encodeId=ecac1e048369e, content=<a href='/topic/show?id=be56234245' target=_blank style='color:#2F92EE;'>#Alnylam#</a>, objectTitle=FDA批准Alnylam的RNAi疗法givosiran治疗罕见遗传病——急性肝卟啉症, objectType=article, longId=183486, objectId=889518348636, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=889518348636, replyNumber=0, likeNumber=105, createdTime=2020-07-26, rootId=0, userName=zz12341244, userId=cfb930846673, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=889518348636, moduleTitle=FDA批准Alnylam的RNAi疗法givosiran治疗罕见遗传病——急性肝卟啉症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=889518348636)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1704840, encodeId=3ed91e04840ff, content=<a href='/topic/show?id=be56234245' target=_blank style='color:#2F92EE;'>#Alnylam#</a>, objectTitle=Alnylam的RNAi疗法Vutrisiran获得FDA快速通道指定，治疗hATTR淀粉样变性, objectType=article, longId=192376, objectId=8eeb1923e6a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8eeb1923e6a6, replyNumber=0, likeNumber=83, createdTime=2020-10-12, rootId=0, userName=zz12341244, userId=cfb930846673, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8eeb1923e6a6, moduleTitle=Alnylam的RNAi疗法Vutrisiran获得FDA快速通道指定，治疗hATTR淀粉样变性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8eeb1923e6a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1704837, encodeId=b1811e048373b, content=<a href='/topic/show?id=be56234245' target=_blank style='color:#2F92EE;'>#Alnylam#</a>, objectTitle=Alnylam的RNA干扰药物Givlaari作为欧盟首例治疗急性肝卟啉症的药物，获得了CHMP的积极评价, objectType=article, longId=187288, objectId=72c718e28817, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=72c718e28817, replyNumber=0, likeNumber=84, createdTime=2020-05-18, rootId=0, userName=zz12341244, userId=cfb930846673, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=72c718e28817, moduleTitle=Alnylam的RNA干扰药物Givlaari作为欧盟首例治疗急性肝卟啉症的药物，获得了CHMP的积极评价, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=72c718e28817)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1704841, encodeId=a9801e0484148, content=<a href='/topic/show?id=be56234245' target=_blank style='color:#2F92EE;'>#Alnylam#</a>, objectTitle=Alnylam/Vir宣布推进RNAi疗法VIR-2703，用于抵抗新冠病毒COVID-19, objectType=article, longId=193613, objectId=b78f193613fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b78f193613fa, replyNumber=0, likeNumber=88, createdTime=2021-02-07, rootId=0, userName=zz12341244, userId=cfb930846673, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b78f193613fa, moduleTitle=Alnylam/Vir宣布推进RNAi疗法VIR-2703，用于抵抗新冠病毒COVID-19, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b78f193613fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1704835, encodeId=51761e048355a, content=<a href='/topic/show?id=be56234245' target=_blank style='color:#2F92EE;'>#Alnylam#</a>, objectTitle=英国NICE批准Alnylam的基因干扰药物Onpattro用于治疗hATTR淀粉样变性, objectType=article, longId=175117, objectId=a1811e511786, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a1811e511786, replyNumber=0, likeNumber=71, createdTime=2020-04-09, rootId=0, userName=zz12341244, userId=cfb930846673, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a1811e511786, moduleTitle=英国NICE批准Alnylam的基因干扰药物Onpattro用于治疗hATTR淀粉样变性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a1811e511786)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1704834, encodeId=18391e048340f, content=<a href='/topic/show?id=be56234245' target=_blank style='color:#2F92EE;'>#Alnylam#</a>, objectTitle=Alnylam的RNAi疗法Onpattro获得欧盟批准治疗hATTR, objectType=article, longId=147844, objectId=5f9e14e84418, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5f9e14e84418, replyNumber=0, likeNumber=75, createdTime=2019-07-14, rootId=0, userName=zz12341244, userId=cfb930846673, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5f9e14e84418, moduleTitle=Alnylam的RNAi疗法Onpattro获得欧盟批准治疗hATTR, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5f9e14e84418)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1704833, encodeId=e1bc1e0483326, content=<a href='/topic/show?id=be56234245' target=_blank style='color:#2F92EE;'>#Alnylam#</a>, objectTitle=RNAi疗法再遭重创 Alnylam新疗法因患者意外死亡被迫中止, objectType=article, longId=79737, objectId=952ee9737a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=952ee9737a3, replyNumber=0, likeNumber=90, createdTime=2017-09-03, rootId=0, userName=zz12341244, userId=cfb930846673, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=952ee9737a3, moduleTitle=RNAi疗法再遭重创 Alnylam新疗法因患者意外死亡被迫中止, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=952ee9737a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1704832, encodeId=7d611e0483249, content=<a href='/topic/show?id=be56234245' target=_blank style='color:#2F92EE;'>#Alnylam#</a>, objectTitle=Alnylam RNAi 胆固醇药物一期实验结果良好, objectType=article, longId=25334, objectId=9b6425334b7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9b6425334b7, replyNumber=0, likeNumber=78, createdTime=2014-04-20, rootId=0, userName=zz12341244, userId=cfb930846673, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9b6425334b7, moduleTitle=Alnylam RNAi 胆固醇药物一期实验结果良好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9b6425334b7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1704831, encodeId=c29f1e04831bc, content=<a href='/topic/show?id=be56234245' target=_blank style='color:#2F92EE;'>#Alnylam#</a>, objectTitle=FDA授予Alnylam RNAi药物ALN-AT3孤儿药地位, objectType=article, longId=23241, objectId=b5832324158, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b5832324158, replyNumber=0, likeNumber=72, createdTime=2013-10-13, rootId=0, userName=zz12341244, userId=cfb930846673, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b5832324158, moduleTitle=FDA授予Alnylam RNAi药物ALN-AT3孤儿药地位, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b5832324158)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Alnylam

2020-05-29

lifestar (审核中...)

前往app查看评论内容

#RNAi药物##Alnylam# #lumasiran#治疗#原发性高草酸尿症1型#

FDA批准lumasiran治疗原发性高草酸尿症1型，Alnylam的RNAi帝国再下一城！

2022-10-11

zz12341244 (审核中...)

前往app查看评论内容

#Alnylam#

RNAi治疗COVID-19：Alnylam与Vir Biotechnology联手开发

2020-08-05

zz12341244 (审核中...)

前往app查看评论内容

#Alnylam#

RNAi巨头Alnylam公司再发力：出击非酒精性脂肪性肝炎（NASH）

2020-11-24

zz12341244 (审核中...)

前往app查看评论内容

#Alnylam#

ERA-EDTA 2020：RNAi疗法公司Alnylam再发力！Lumasiran治疗1型原发性高草酸尿症III期临床成功

2021-04-30

zz12341244 (审核中...)

前往app查看评论内容

#Alnylam#

FDA为Alnylam的RNAi疗法Lumasiran授予优先审查，用于治疗1型原发性高草酸尿症

2020-10-04

zz12341244 (审核中...)

前往app查看评论内容

#Alnylam#

Alnylam的第二款RNAi药物Givlaari，获得欧盟批准治疗肝卟啉症

2020-09-14

zz12341244 (审核中...)

前往app查看评论内容

#Alnylam#

FDA批准Alnylam的RNAi疗法givosiran治疗罕见遗传病——急性肝卟啉症

2020-07-26

zz12341244 (审核中...)

前往app查看评论内容

#Alnylam#

Alnylam的RNAi疗法Vutrisiran获得FDA快速通道指定，治疗hATTR淀粉样变性

2020-10-12

zz12341244 (审核中...)

前往app查看评论内容

#Alnylam#

Alnylam的RNA干扰药物Givlaari作为欧盟首例治疗急性肝卟啉症的药物，获得了CHMP的积极评价

2020-05-18

zz12341244 (审核中...)

前往app查看评论内容

#Alnylam#

Alnylam/Vir宣布推进RNAi疗法VIR-2703，用于抵抗新冠病毒COVID-19

2021-02-07

zz12341244 (审核中...)

前往app查看评论内容

#Alnylam#

英国NICE批准Alnylam的基因干扰药物Onpattro用于治疗hATTR淀粉样变性

2020-04-09

zz12341244 (审核中...)

前往app查看评论内容

#Alnylam#

Alnylam的RNAi疗法Onpattro获得欧盟批准治疗hATTR

2019-07-14

zz12341244 (审核中...)

前往app查看评论内容

#Alnylam#

RNAi疗法再遭重创 Alnylam新疗法因患者意外死亡被迫中止

2017-09-03

zz12341244 (审核中...)

前往app查看评论内容

#Alnylam#

Alnylam RNAi 胆固醇药物一期实验结果良好

2014-04-20

zz12341244 (审核中...)

前往app查看评论内容

#Alnylam#

FDA授予Alnylam RNAi药物ALN-AT3孤儿药地位

2013-10-13

科室
- - 订阅+
  - 更多科室
工具
服务